NIPH Clinical Trials Search

Oxytocin Receptor PET Study in Healthy Volunteers

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	none
Date of first enrollment	10/02/2026
Target sample size	12
Countries of recruitment
Study type	Interventional
Intervention(s)	Healthy volunteers will receive an intravenous injection of the OXTR-PET tracer [11C]OCS5 followed by PET imaging. Blood samples necessary for kinetic analysis will also be collected. To evaluate the relationship between brain oxytocin receptor distribution and social behavior/psychological function, social behavior assessments and questionnaires were administered. Furthermore, MRI examinations were performed to assess the relationship with brain function and brain morphology indices. Blood samples were collected to confirm safety.

Outcome(s)

Primary Outcome

Brain Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection

Secondary Outcome

Safety and Pharmacokinetics of the OXTR-PET Tracer [11C]OCS5 Estimated Radiation Exposure Following Administration of the [11C]OCS5 Injection Association between Brain Distribution Following Administration of OXTR-PET Tracer [11C]OCS5 Injection and Individual Differences in Social Behavior and Mental Functioning (Frequency of Nonverbal Information Utilization in the Nonverbal Judgment Task (NVJ), Reaction Time (RT) and Eye Gaze (EG) During the Task, Social Responsiveness Scale (SRS), Autism Quotient (AQ), Stress and Anxiety Assessment (State and Trait Anxiety: STAI), Social Functioning Scale (SFS), Socioeconomic Status (SES) Gender Differences in Brain Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection Relationship Between Brain Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection and OXT Blood Concentration Relationship Between Brain Distribution Following Administration of the OXTR-PET Tracer [11C]OCS5 Injection and Brain Function/Structure Indicators Measured by MRI

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	< 55age old
Gender	Both
Include criteria	(1) Males and females aged 18 years or older but under 55 years at the time of consent acquisition (2) Healthy individuals with no past medical history (excluding infectious diseases that do not leave sequelae) or current medical conditions (3) Individuals for whom written consent to participate in this study has been obtained from the subject themselves
Exclude criteria	(1) Individuals diagnosed with a mental disorder or intellectual disability (2) Use of psychotropic medications within the past 6 months (3) Individuals who are pregnant, breastfeeding, or may be pregnant (4) History of hypersensitivity to oxytocin (5) History of epileptic seizures or head trauma with loss of consciousness lasting 5 minutes or longer (6) History of alcohol-related disorders or other substance-related disorders (7) Individuals with serious concomitant diseases (8) Individuals with severe allergies or idiosyncrasies, such as anaphylaxis (9) Individuals unable to obtain consent to use contraception during the study period (10) Individuals who participated in another PET study (involving radiation exposure) within one year prior to obtaining consent (11) Individuals deemed ineligible for this study by the principal investigator (or co-investigator)